<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Butterman, Eric</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TMC435 Effective in the Treatment of HCV Genotype 1 Infection</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Both the PILLAR [TMC435-C205; NCT00882908] and ASPIRE [TMC435-C206; NCT00980330] trials demonstrated that TMC435 (an oral inhibitor of the hepatitis C virus NS3/4A protease) administered once-daily with pegylated interferon alpha-2a (PegIFNa-2a) and ribavirin (RBV) is safe, has potent antiviral activity, and shortens total treatment by 24 weeks compared with PegIFNa-2a/RBV alone.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>